Pigmented purpuric dermatosis (PPD) is an all-encompassing term to describe a group of cutaneous lesions that have in common petechiae and bronze discoloration of the skin with primary localization to the legs; its histomorphologic features involve superficial lymphocytic infiltration with attendant hemorrhage. [1] [2] [3] [4] [5] [6] [7] PPD can be further characterized into Schamberg disease, Majocchi purpura, Gougerot-Blum purpura, lichen aureus, and the eczematoid purpura of Doucas and Kapetanakis. [2] [3] [4] In Schamberg disease, cayenne pepper-like lesions with lower extremity localization are observed. Majocchi purpura, or purpura annularis telangiectodes, has as its clinical hallmarks reddish annular patches or plaques on the buttocks, trunk, and proximal extremities. 2 Lichen planus-like papules with superimposed purpura are typical for the Gougerot-Blum variant. In lichen aureus, golden, slightly indurated scaly solitary plaques over the medial malleolus are observed. There is a demographic predilection to involve young to middle-aged adult males is observed. 4, 5 Eczematous alterations in a background of purpura define eczematoid pigmented purpuric dermatosis of Doucas and Kapetanakis. [1] [2] [3] [4] [5] [6] [7] A number of associations have been made, including venous stasis, diabetes mellitus, and rheumatoid arthritis. 6 Drugs have been described as a triggering factor in cases of PPD showing lymphoid atypia, with 1 study showing a significant percentage of such cases resolving with appropriate drug modulation. Among the implicated drugs are nonsteroidal anti-inflammatory agents, sedatives, antihypertensives, drugs with antihistaminic properties, and lipid-lowering agents. 7 There is an emerging body of clinical, phenotypic, and molecular data suggesting that PPD may represent an insidious epitheliotropic T-cell dyscrasia. [7] [8] [9] [10] [11] [12] [13] [14] [15] Although progression to mycosis fungoides (MF) is described, the literature precedent in this regard is limited, with only 11 reported cases. 9, 11, 12, [14] [15] [16] However, it is possible that underreporting accounts for the few patients described in the literature. We examined the molecular and phenotypic features of 43 cases of PPD to further explore the hypothesis that PPD is a form of cutanaeous T-cell dyscrasia.
Materials and Methods

Case Selection
Case selection was based on a clinical and pathologic diagnosis of PPD. We prospectively encountered 42 patients from July 2003 through September 2006. There was no bias in the selection of these cases. Specifically, cases with more unusual clinical manifestations were not specifically selected or examined. Essentially all cases with a clinical and pathologic diagnosis of PPD were comprehensively analyzed from a combined clinical, light microscopic, and phenotypic perspective. The inherent bias could reflect the fact that patients with PPD who undergo biopsy are more likely to have a clinical course that deviates from what is deemed classic PPD, at least from a clinical perspective.
In each case, skin biopsies with phenotyping and molecular studies were performed as part of the routine diagnostic assessment. Physicians' offices were contacted in all cases to obtain a comprehensive clinical and drug history; a response was obtained in some cases.
Immunophenotyping
Initially, 5-µm sections of formalin-fixed, paraffinembedded tissues were placed on positively charged slides (Fisher, Pittsburgh, PA). Routine deparaffinization from xylene to 95% alcohol and rehydration before patented microwave antigen recovery were carried out on the Varistainer Gemini (ThermoShandon, Pittsburgh, PA). Deparaffinization included a 30-minute methanolic peroxide block for endogenous peroxidase activity. The antigen recovery step (Microwave Antigen Retrieval, US patent 5,244,787) was carried out in a laboratory microwave oven (model H2550, Energy Beam Sciences, Agawam, MA). The slides on which the CD62L and CD7 assays were conducted were placed in Tissue Tek slide holders and staining dishes (Miles, Elkhart, IL) and submersed in 200 mL of EDTA buffer, pH 8.0 (Zymed Laboratories, South San Francisco, CA). The slides for CD7 clone CBC.37 were placed in 200 mL of Citra Plus (BioGenex, San Ramon, CA). Both staining dishes were placed in the microwave oven for 5 minutes on the high energy setting; up to 50 mL of distilled water was added to replenish the evaporative loss, and the holder was returned to the microwave oven for an additional 5 minutes on the high setting. The holder and slides were then removed from the oven and cooled for 20 minutes before continuing the immunostaining procedure.
The slides were placed into tris(hydroxymethyl) aminomethane (Tris)-buffered saline (TBS) buffer and prepared for loading on the DAKO Autostainer (DAKO, Carpinteria, CA). The detection of the antigens was performed by using a 2-step immunohistochemical procedure. The primary antibodies were applied for a 30-minute incubation, followed by a TBS rinse and 5-minute incubation. The peroxidase-labeled dextran polymer (K4001, DAKO) was applied and incubated for 30 minutes. The slides were rinsed with TBS. The chromogen, diaminobenzidine/peroxide (K3466, DAKO), was applied twice for 5 minutes. The slides were then rinsed thoroughly with deionized water. The slides were returned to the Varistainer Gemini for counterstaining with Gill 2 Hematoxylin (product No. 6765007, ThermoShandon) for 30 seconds. The bluing agent (product No. 6769001, ThermoShandon) was applied for 10 seconds. The slides were then dehydrated through graded alcohols to xylene. Slides were coverslipped using Consul-Mount (product No. 9990440) on a Consul automated coverslipper (ThermoShandon).
The percentage of cells within the epidermis and dermis manifesting positivity with CD62L and CD7 relative to CD3 was determined. The value was based on a subjective semiquantitative and qualitative assessment. Average percentages in each category were calculated for the relative diminution of CD62L and CD7 expression based on individual values given for each case. CD62L and CD7 are established pan-Tcell markers for which a significant decrement in the extent of expression of one or both markers is seen in the setting of cutaneous lymphoid dyscrasia (CLD), including MF and large plaque parapsoriasis. 17, 18 A Foxp3 assay was done on select cases based on tissue availability. The primary antibody used was mouse antihuman Foxp3 at a dilution of 1:200 and incubated for 1 hour at room temperature. Foxp3 is a marker of regulatory T-cell activity in which this particular cell population may have a critical role in attenuating emerging T-cell clones. In this regard, recent studies have inversely correlated the extent of Foxp3 expression with a more aggressive clinical course in the setting of mycosis fungoides. 19 The detection system used was MACH 3 (catalog No. M3M530L, Biocare Medical, Concord, CA), a biotin-free polymer detection kit. The substrate chromogen used was DAB+ (catalog No. K3468, DAKO). The antibody was Foxp3, a mouse antihuman antibody (clone 236A/E7, catalog No. 14-4777, eBioscience, San Diego, CA). The slides were then counterstained with hematoxylin (Richard-Allan Scientific, Kalamazoo, MI), dehydrated through graded ethanol solutions, and coverslipped.
Multiplex Polymerase Chain Reaction Assay
Patient materials used for study consisted of formalinfixed, paraffin-embedded skin biopsy specimens.
DNA isolation was performed by standard protocols using a QIAGEN BioRobot M48 workstation (QIAGEN, Valencia, CA) and MagAttract (magnetic separation; QIA-GEN) purification technology. Assays for T-cell receptor β were performed according to the polymerase chain reaction (PCR) protocol of the BIOMED-2 Concerted Action BMH4-CT98-3936. 20 All PCR reactions were done using complete kits purchased from In Vivo Scribe Technologies, Carlsbad, CA. Reaction conditions and cycling conditions were used according to the standardized kit protocol. Standard positive and negative control experiments were performed in parallel for all specimens.
For T-cell receptor β, a multiplex PCR assay with 23 consensus variable (V), 2 specific diversity (D), and 13 specific joining (J) primers was used for amplification of gene rearrangements. This multiplex PCR assay consisted of 3 separate reactions (tubes A, B, and C), to ensure detection of complete V-J (tubes A and B) and incomplete D-J (tube C) rearrangements. All J primers were labeled at their 5' end with 6'FAM (6-carboxyfluorescein, Applied Biosystems, Foster City, CA) for automated fluorescent fragment analysis (GeneScanning, Applied Biosystems) of the PCR product.
PCR products were analyzed with GeneScanning software (Applied Biosystems) by exact size determination and quantitative measurement of fluorescence intensity after electrophoresis on a high-resolution polyacrylamide gel on an ABI PRISM 310 sequencer (Applied Biosystems). Briefly, the fluorochrome-labeled, single-strand (denatured) PCR products are size separated in a capillary-based denaturing polyacrylamide sequencing polymer and detected via automated scanning with a laser. For polyclonal products, this procedure results in a gaussian distribution of multiple peaks, representing a multitude of different PCR products derived from variable immunoglobulin locus-specific gene rearrangements. For monoclonal products, there is a single peak consisting of 1 type of PCR product derived from a single immunoglobulin locus-specific gene rearrangement. In some cases, depending on the percentage of clonal lymphocytes in a given sample intermixed with nonclonal lymphocytes, it was possible to detect the emergence of 1 or more clonal populations in a polyclonal background. The precise determination of the size of the PCR product in clonal proliferations was used for follow-up or comparisons of different specimens for a given patient.
When 1 or 2 dominant T-cell peaks were observed, the infiltrate was held to be clonal; a dominant clone was characterized by a base pair size that was more than twice the size of the next highest peak. When 3 to 5 distinct T-cell clones exceeded at least twice the base pair size of the next highest peak in the remainder of the T-cell population defining the background gaussian distribution, a diagnosis of oligoclonality was made. Because fluorescent intensity correlates with the number of cells manifesting a particular T-cell rearrangement, an estimated percentage occupied by that particular molecular weight clone could be determined.
DNA Extraction and Amplification
DNA from the paraffin sections was isolated by xylene deparaffinization, Proteinase K digestion, organic extraction, and ethanol precipitation. Five-to ten-µm sections of tissues fixed in 10% neutral buffered formalin and embedded in paraffin were cut on a clean microtome and placed in a microcentrifuge tube. The tissue samples were deparaffinized in xylene for 30 minutes and pelleted in an ultracentrifuge. The deparaffinization step was repeated, and the pellet was washed with 100% ethanol twice and air dried. The tissue was resuspended in cell lysis solution and digested with Proteinase K overnight at 55°C. The tubes were heated to 95°C for 10 minutes to inactivate Proteinase K and centrifuged. The supernatant was recovered and subjected to organic extraction (phenol) and washed with 100% alcohol to precipitate the DNA. The DNA was then air dried and reconstituted in Gentra Systems Puregene DNA rehydration solution (Gentra Systems, Minneapolis, MN) and stored at -80°C. Concentration of the DNA was determined directly by the absorbance in the 260-nm UV regions using a spectrophotometer.
Results
There were 43 patients with clinical features and biopsy results consistent with PPD. The patients ranged in age from 3 to 92 years (mean age, 45.0 years); the age of 1 patient was unknown. There were 2 broad categories: clonally restricted PPD and PPD with a polyclonal molecular profile. Each category is described separately with respect to the clinical, morphologic, phenotypic, and molecular features.
Monoclonal PPD
Clinical Features
❚Table 1❚ shows the clinical features of the patients with monoclonal PPD. There were 21 patients, including 12 men, 4 women, 2 boys, and 3 girls aged 3 to 84 years (mean age, 47.1 years). The patients had purpuric macules, patches, and plaques ranging from 1 to 5 cm and involving the legs and feet in 12, thighs in 3, trunk in 3, forearms in 3, buttocks in 2, and face in 1. In 13 patients, the lesions manifested a distribution that included areas of the skin outside the legs. The duration of lesions ranged from 3 weeks to 20 years (mean, 3.8 years).
In 10 patients (8 men, 1 woman, and 1 girl), progression to cutaneous T-cell lymphoma occurred. In 9 of the patients, the form of cutaneous T-cell lymphoma was MF, and in 1 patient, nodular lesions characteristic of primary cutaneous small and medium-sized pleomorphic T-cell lymphoma recently developed. Their age range was 32 to 79 years (mean age, 61 years), and the duration of disease was more than 2 years in all but 1 patient. All patients had skin lesions that involved additional sites other than the legs. The patients had either an established clinical diagnosis of PPD before evolution to cutaneous T-cell lymphoma, or, at the time of the diagnosis of cutaneous T-cell lymphoma, background clinical features of PPD ❚Image 1❚ and ❚Image 2❚.
We were able to document a comprehensive drug history in 7 cases. The vast majority of patients (6/7 [86%]) for whom the history was available were taking at least 1 drug that has been implicated as a trigger of PPD and druginduced reversible lymphoid dyscrasia. These drugs include ❚Image 1❚ The patient is a 56-year-old man with pigmented purpuric dermatosis temporally associated with antihistamine use.
❚Image 2❚ The patient is a 67-year-old man with a long-standing history of pigmented purpuric dermatosis in whom progressive disease developed, eventuating in mycosis fungoides.
antidepressants, angiotensin-converting enzyme inhibitors, histamine 1 and 2 receptor antagonists, antiepileptic drugs, and phenothiazines 16 (Table 1) . Drug histories could not be obtained for the remaining 14 cases.
Histopathologic Findings
In all cases, there was a superficial lymphocytic infiltrate with variable epitheliotropism associated with RBC extravasation unaccompanied by mural or luminal fibrin deposition ❚Image 3❚ and ❚Image 4❚. The pattern of migration was epidermotropic, as the cells assumed a passive pattern of infiltration in the epidermis, largely unaccompanied by dyskeratosis or spongiosis. Some cases showed hemosiderin deposition. In all, examination under oil immersion (100× objective) revealed a cell population dominated by small lymphocytes with nuclear contour irregularity; in 16 of 21 cases, cerebriform lymphoid cells were identified in varying numbers ❚Image 5❚. The acrosyringia and suprapapillary plates were selectively involved in some cases. A lichenoid pattern was seen in 14 cases, often accompanied by epidermal attenuation. The cases of longer duration typically had a lichenoid pattern.
The patients in whom MF developed had concomitant background features of PPD; the degree of lymphoid infiltration and atypia was greater than that seen in prior biopsy specimens of PPD in these patients (Images 3-5) ❚Image 6❚ and ❚Image 7❚. It was easy to identify cells in the epidermis in which the cytologic atypia exceeded that of the dermal lymphocytes; Pautrier microabscesses were identified. In the patient with progression to primary cutaneous pleomorphic T-cell lymphoma, the lesions manifested a pandermal nodular small and intermediate-sized atypical lymphocytic infiltrate. There were zones of a superficial band-like lymphocytic infiltration with associated hemorrhage defining a pattern compatible with background morphologic features of PPD. In 4 cases, concomitant granulomatous inflammation ❚Image 3❚ The specimen is from a 38-year-old man with a long-standing history of pigmented purpuric dermatosis. A biopsy specimen from 2003 shows a superficial interstitial and perivascular lymphocytic infiltrate with concomitant RBC extravasation (×100).
❚Image 4❚ There is focal migration of lymphocytes into the epidermis. The pattern of migration is passive. Note the extensive RBC extravasation (×200).
❚Image 5❚ Examination under oil reveals that the lymphocytes within the epidermis, although small, show nuclear contour irregularity, including cells with a cerebriform outline (×1000).
represented by 3 cases of MF and 1 case of PPD without apparent progression to MF was present.
Immunophenotyping
Immunophenotypic results for 21 patients with monoclonal PPD are given in ❚Table 2❚. In 18 of 20 cases, the lymphoid phenotype showed a dominance of CD4+ over CD8+ cells in ratios of at least 4:1. There was a substantial reduction of CD7 expression in 18 cases with relative preservation of expression of this marker in 2 cases ❚Image 8❚. In all cases with reduced expression, all had a reduction of expression by at least 70% except 1 case that manifested a 20% reduction and 1 case demonstrating a reduction of expression of less than 10%. The expression of CD62L was reduced by 90% or greater in 15 cases, by 50% in 1 case, and by 5% in 1 case; CD62L expression was not studied in 4 cases. Preservation of CD5 expression was seen in all cases. The cells showing preservation of CD62L and CD7 expression were smaller lymphocytes without significant nuclear atypia. Foxp3 was expressed by 10% of the cells in one case and 20% of cells in another case. Additional cases were not assessed.
In the case of a 13-year-old boy, there was only a 50% reduction in CD7 at an earlier time when the T-cell repertoire was oligoclonal. This is in contradistinction to a loss of CD7 in excess of 95% 6 months later, when a monoclonal pattern emerged.
Molecular Results
Monoclonality was seen in all cases, excluding an oligoclonal (restricted repertoire) pattern in 5 cases ❚Image 9❚, ❚Image 10❚, ❚Image 11❚, and ❚Image 12❚ ( Table 2) .
Of the monoclonal cases, 5 patients had multiple biopsy specimens (Images 9 and 12) procured during periods of 6 months to 3 years. In 3 of the monoclonal cases with multiple biopsies, progressive disease eventuating in MF was observed. In all of these cases, identical dominant T-cell clones were observed in the different biopsy samples. The fourth patient had classic lesions of PPD in 2004 and then in 2005, had nodular lesions compatible with pleomorphic Tcell lymphoma. Molecular studies performed in this case failed to disclose commonality in the T-cell clones between the lesions of PPD and those compatible with pleomorphic T-cell lymphoma.
For the oligoclonal cases, multiple biopsy specimens were procured in 3 cases at different sites and/or during different periods. One patient had multiple biopsies at different sites at the same time; another had multiple biopsies during a 17-month period; a third patient had biopsies from 2 sites at the same time. The same restricted repertoire was seen at all sites at all times in each patient. Of these 3 patients, 2 had MF. In particular, a 44-year-old man had one biopsy specimen from the back compatible with MF, whereas the second biopsy specimen from the ankle showed lichen aureus. The biopsy ❚Image 6❚ A biopsy done 1 year later on the patient illustrated in Images 3 and 4 shows a similar pattern of superficial lymphocytic infiltration and hemorrhage. However, there is enhanced intraepidermal and dermal atypia that is apparent even under lower power magnification defined by significant nuclear hyperchromasia and nuclear size variation (×200).
❚Image 7❚ There is passive colonization of the epidermis by atypical hyperchromatic lymphocytes (×400). A diagnosis of mycosis fungoides arising in a background of pigmented purpuric dermatosis was made. This diagnosis was correlated with other aspects of the clinical manifestations, including development of large, scaly patches involving much of the truncal area arising in a background of classic pigmented purpuric dermatosis.
specimen from the back demonstrated a monoclonal profile, whereas the ankle biopsy specimen showed an oligoclonal restricted repertoire pattern. Nevertheless, it contained the same dominant peak that defined the monoclonal profile from the back biopsy specimen.
Polyclonal PPD
Clinical Features
❚Table 3❚ shows the clinical features of the patients with polyclonal PPD. There were 22 patients, including 15 men, 6 women, and 1 boy, aged 17 to 92 years (mean age, 42.8 years; age unknown for 1 patient). The patients had purpuric macules, patches, and plaques ranging from 1 to 3 cm. Of the 22 patients, lesions involved the legs and feet in 15, thighs in 2, trunk in 2, forearms in 3, and buttocks and sacrum in 2. Only 6 patients had lesions that were at sites other than the leg. The duration of lesions ranged from 4 weeks to 7 years (mean, 1.6 years). In no patient did progression to MF occur.
In 1 case, a 33-year-old woman, the lesions developed during a several-week period involving the face, hands, and feet. A significant history related to antidepressant or antiepileptic drug use was found in nearly half of the patients ❚Image 8❚ There is a significant reduction in the expression of CD7 (×200). ❚Image 9❚ The molecular profiles from 3 separate biopsy specimens from the case illustrated in Images 3 through 6 show a dominant T-cell population at base pairs (bp) of 189 in a polyclonal background. Only 1 biopsy specimen was compatible with mycosis fungoides, whereas the other 2 showed features characteristic of pigmented purpuric dermatosis. Nevertheless, in all cases, the same T-cell population was identified. bp, base pairs.
for whom data were available. In 1 patient who discontinued the antidepressant, resolution of the lesions occurred. She had received antidepressants for a few years; recommendation was given to discontinue bupropion, which led to resolution of the lesions during a period of roughly 4 months. In a second patient, similar lesions developed while taking bupropion. Overall, we were able to document comprehensive drug histories in 14 cases. Among the drugs used were angiotensin 1 receptor inhibitors, serotonin reuptake inhibitors, and histamine 1 receptor antagonists (Table 2) . Drug histories were not obtained for the other 8 patients.
Histopathologic Findings
All biopsies demonstrated a superficial interstitial and perivascular lymphocytic infiltrate with RBC extravasation and migration of lymphocytes into the epidermis. There was a dense band-like infiltrate in 13 of 22 cases. The infiltrate was predominated by small lymphoid cells. The other 9 cases showed a superficial perivascular infiltrate. In 1 pediatric case, there was deep perivascular and interstitial extension. The cases with a band-like infiltrate often had epidermal attenuation. Lymphoid atypia was seen in 16 of 22 cases and 22  70  90  +  23  60-70  70  +  24  90  90  +  25  80  50  +  26  >85  >95  +  27  70-80  90  +  28  50  ND  +  29  95  75  +  30  50  50  +  31  90  90  +  32  90  60  +  33  80  80  +  34  10  10  +  70  70  +  35  80  ND  +  36  90  90  +  37  ND  ND  +  38  10  90  +  39  ND  ND  +  40  30  30  +  41  ND  10  +  42  70  70  +  43 50 ND + ND, not done; +, predominance of CD8+ or CD4+ cells or the equal representation of both. * Relative diminution (%) of CD7-and CD62L-expressing cells. comprised mild nuclear atypia. Cerebriform small lymphoid cells were present in 5 cases. There was a lack of other inflammatory cells except for the pediatric cases, in which plasma cells were identified.
Immunophenotyping
Immunophenotypic results for 22 patients with polyclonal PPD are given in ❚Table 4❚. In 16 of 22 cases in which the lymphoid phenotype was assessed, there was a dominance of CD4+ over CD8+ cells in ratios of at least 4:1. There was dominance of CD8 cells in 4 cases, and in 2 cases, there was a reduction in the CD4/CD8 ratio. In 19 cases in which CD7 expression was assessed (including 2 samples for case 34), there was a greater than 85% reduction of CD7 expression in 6 cases, a 70% to 80% reduction in 8, a 50% reduction in 3, a 30% reduction in 1, and a 10% reduction in 2. In the 17 cases in which it was assessed (including 2 samples for case 34), the expression of CD62L was reduced by greater than 90% in 1 case, by 70% to 90% in 11 cases, by 30% to 60% in 4 cases, and by less than 30% in 2 cases. CD62L expression was not studied in 5 cases. Expression of Foxp3 was assessed in 5 cases and was expressed in 15% to 30% of the infiltrate in all 5.
Molecular Results
All cases showed a polyclonal pattern.
Discussion
There is an increasing body of literature that suggests that PPD should be categorized as a form of CLD. The earlier studies described patients with PPD that presaged the development of MF. The classic article by Barnhill and Braverman 11 was an account of young or middle-aged males with PPD who manifested more widespread distribution compared with the classic lower extremity distribution. The clinical hallmarks of progression to MF included large areas of confluence, a superimposed violaceous hue, and pruritus often exacerbated by a hot shower. 11 Other isolated case reports have also described a male predominance. 8, 9, 12, 14 In our series, more than 50% of patients in the monoclonal group had extensive multifocal disease; in 8 of these patients, progressive disease compatible with MF developed. Multifocal disease was seen in only 25% of patients whose biopsies revealed a polyclonal pattern; in none of these patients was there progression to MF. In our series, there was a definite male predilection for monoclonal variants of adult onset PPD (>80%). In contrast with the adult cases, 3 of 4 pediatric cases of clonally restricted PPD occurred in girls.
From a histologic perspective, there were differences and points of commonality between the monoclonal and polyclonal groups. In both groups, a lichenoid pattern was the most common morphologic feature and typically correlated with longer duration of disease. A small lymphocyte-dominant population was common to both. However in the monoclonal group, lymphoid atypia was seen in all cases, and, in most cases, cerebriform morphologic features could be seen. In the polyclonal group, although lymphoid atypia was seen in 75% of cases, it was mild and cerebriform lymphocytes were infrequent. Other features, such as the epidermotropic pattern of migration of lymphocytes, were common to both. In the current series, there was no differential expression between the extent of intraepidermal lymphoid atypia vs dermal atypia, excluding the cases of MF arising in a background of PPD. In previous studies, the greater lymphoid atypia in the dermis was a clue that favored nonlymphomatous states over MF. 7 Phenotypically, 18 of 21 cases of monoclonal PPD exhibited a dominance of CD4 lymphocytes, whereas the polyclonal pattern could show a dominance of CD8 lymphocytes or increased numbers of CD8 lymphocytes. It is possible that the CD8 lymphocytes in this setting are reactive cells responding to an aberrant CD4 cell population, defining a potential role of these cells in attenuating emerging T-cell clones.
In the monoclonal group, there was significant diminution of CD7 and CD62L expression, often in excess of 90%, cognate to the degree of reduced expression seen in fully evolved cases of MF. In contrast, in drug-induced reversible Tcell dyscrasias and other related reactive lymphomatoid states such as lymphomatoid connective tissue disease and lymphomatoid responses triggered by viral infection, the magnitude of diminished expression of CD7 and CD62L is typically less profound than was seen in our cases. 17, 18 Furthermore, in reactive lymphomatoid states, reduced expression of one but not both of these markers is typical 17, 18 ; one study suggested relative preservation of CD62L expression compared with that of CD7 in reactive lymphomatoid states. 17, 18 Even our polyclonal cases of PPD showed substantial reductions in the expression of CD7 and CD62L, comparable with MF and with the monoclonal cases of PPD. Nevertheless, there was a greater number of cases showing a lesser degree of reduction for these 2 markers, although the differences did not achieve significance. The ubiquitous finding of this pattern of phenotypic aberration is further evidence supporting the concept that PPD is a form of CLD. The phenotypic profile per se did not seem to be a predictor of disease progression.
The question obviously arises regarding the distinction from light microscopic, phenotypic, and molecular perspectives between purpuric MF and monoclonal variants of PPD. This distinction remains to a large extent a clinical one. It is likely that the vast majority of cases of purpuric MF arise in a background of PPD. Such a variant is illustrated in Image 2. When the size of the confluent areas of purpura approaches that seen in patch and plaque stage MF and/or there are supervening poikilodermatous changes along with pruritus, the clinical suspicion should be one of disease progression to MF. Corroborative evidence from a phenotypic perspective includes the presence of Pautrier microabscesses in the epidermis and large cerebriform lymphocytes within the epidermis. Extensive smaller purpuric lesions in a clinically asymptomatic patient would not suggest purpuric MF. It should be emphasized that the identification of cerebriform lymphocytes in the epidermis, although in the absence of Pautrier abscesses, along with clonality and variable losses of CD7 and CD62L could still be within the spectrum of PPD. Morphologic features suggesting disease progression would include Pautrier microabscesses, large cerebriform lymphocytes in the epidermis, and excessive intraepidermal lymphoid atypia that exceeds the degree of dermal atypia.
We had the opportunity to examine Foxp3 expression in only a few cases; however, in the 7 cases examined, PPD does not seem to be a disease of regulatory T cells. Because T-regulatory cells may attenuate the extent of clonal T-cell proliferation, one would surmise that more Foxp3 expression is observed in cases of polyclonal PPD than cases showing a monoclonal pattern. 19, 21 Earlier studies have demonstrated clonality in PPD. 7-9,13 Almost 50% of the cases in our study showed a monoclonal or oligoclonal pattern. From a molecular perspective, the demonstration of an identical T-cell clone at multiple sites over time in several of our patients is corroborative evidence that this process is a clonally driven one without a discernible antigenic trigger. Similar findings of a maintained constant clonotype unrelated to antigenic stimulation is a phenomenon seen in MF and other forms of cutaneous T-cell lymphoma. The molecular profile mirrored disease progression. For example, Anatomic Pathology / ORIGINAL ARTICLE one patient had a single dominant clonally restricted T-cell population in a lesion of MF; the same T-cell population was present in concert with other less dominant unrelated peaks in a classic ankle lesion of lichen aureus. In another patient, a greater dominance of the T-cell clone from a quantitative perspective was present in a lesion of fully evolved MF compared with the identical base pair size peak in a lesion of PPD. Both cases lend further support for our hypothesis that PPD is a form of CLD that can potentially progress to MF.
It should also be emphasized that the failure to identify clonality in cases of PPD may define what is in essence a false-negative result. Specifically, the presence of a few T-cell clones, none of which are dominant, could define an initial profile interpreted as being polyclonal, although at any point, any of these clones may emerge to define a dominant T-cell clonotype (ie, clonality).
In the monoclonal and polyclonal groups of PPD, a positive drug history could be obtained, with the most commonly implicated class of drugs the antidepressants. We have shown in an earlier study that antidepressants are associated with the development of clonally restricted T-cell infiltrate and with a significant suppression in T-cell function. 22, 23 It is possible that there is a selective down-regulation of the regulatory Tcell population, the sequelae of which would be an attenuated response to control the emergence of various antigen responding T-cell clones.
An important issue that needs to be addressed regards the categorization of all lesions of PPD as forms of CLD. One could argue that the persistence of lymphocytic infiltrates in the skin in the absence of an antigenic trigger could be enough to warrant the designation of CLD. One view would be to consider only the cases of PPD with clonal restriction as forms of CLD. In contrast, the cases that show a classic lower extremity localization without identification of clonality might be better treated as a benign inflammatory dermatosis. There is, however, a potential problem with this approach to categorization of PPD. Specifically, clonality should not be viewed as the sine qua non of a dyscrasia. There are many cases of obvious CLD, including overt T-cell lymphoma, in which the clonality studies are negative. Furthermore, we have seen cases progressing from a classic lower extremity-confined form of CLD with polyclonality to cases that show progressive disease with a clear-cut emerging T-cell clone. Retrospective review, however, of the gel graphs in those cases showed a dominant peak in the polyclonal gel corresponding to what truly emerges as monoclonal in subsequent gels. Hence, a logical and careful distinction between nondyscrasia PPD and dyscrasia PPD may be very difficult and may not be practical from a therapeutic perspective.
Given the persistent waxing and waning nature of PPD, the clinical progression in some cases to MF, and a phenotypic and molecular profile similar to that defining MF, we believe that there is sufficient evidence to justify the categorization of PPD as a form of CLD. In this prospective case series, only the cases of PPD with a restricted T-cell clonotype progressed to MF. Cases of PPD with a polyclonal population of T cells did not progress to MF, despite substantial reductions in CD7 and CD62L expression, suggesting that clonality is a better marker for potential disease progression. In our view, cases of clonally restricted PPD, especially in the setting of widespread disease, should be treated in a manner analogous to that for early patch stage MF. Our findings validate the concept of stratification of PPD according to molecular profile. Up-regulation of Foxp3 cells as a means of controlling disease progression is an interesting avenue to explore with respect to further therapeutic intervention.
